COGNITION THERAPEUTICS INC
No SEC Form 4 filings for $CGTX in the last 30 days.
COGNITION THERAPEUTICS INC (CGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622462d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update Purchase, NY – August 6, 2026 – Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing pr
The article says Canada’s biotech sector has seen a strong 12-month run, with listed companies raising $2.4 billion on public markets and excluding Apotex’s $1.5 billion June IPO. It highlights several Canadian biotechs, especially AbCellera Biologics, which plans to report key human efficacy results this quarter for a menopause hot-flash treatment. It also notes foreign investors dominate funding.
Cognition Therapeutics said the FDA, in written meeting feedback, agreed that psychosis in dementia with Lewy bodies (DLB) could support an approvable outcome and aligned on key aspects of a pivotal NDA trial for zervimesine (CT1812). The Phase 3 program is expected to start mid-2027; it will randomize patients to 100 mg once-daily zervimesine vs placebo for nine months, using NPI as a primary endpoint.
Over the past 7 days, alphai's AI scored 2 news stories mentioning CGTX (COGNITION THERAPEUTICS INC). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent CGTX coverage spans financial news, earnings and sector analysis.
Near-term trading focus is on FDA alignment and the updated Phase 3 timeline, plus cash runway into Q4 2027.
Congruence is included as an example, not as a source of new information.
FDA meeting minutes alignment reduces regulatory uncertainty for zervimesine’s pivotal NDA path, supporting a clearer Phase 3 execution plan.
Routine corporate governance vote results; no new financial guidance or transaction disclosed.
Conference participation is a catalyst-adjacent update, but the release provides no new clinical datapoints or regulatory decisions.
alphai scores every news story that mentions CGTX with an AI model for sentiment and relevance, and aggregates insider trades from COGNITION THERAPEUTICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
COGNITION THERAPEUTICS INC (CGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622462d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update Purchase, NY – August 6, 2026 – Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing pr
5 min readThe article says Canada’s biotech sector has seen a strong 12-month run, with listed companies raising $2.4 billion on public markets and excluding Apotex’s $1.5 billion June IPO. It highlights several Canadian biotechs, especially AbCellera Biologics, which plans to report key human efficacy results this quarter for a menopause hot-flash treatment. It also notes foreign investors dominate funding.
7 min readCognition Therapeutics said the FDA, in written meeting feedback, agreed that psychosis in dementia with Lewy bodies (DLB) could support an approvable outcome and aligned on key aspects of a pivotal NDA trial for zervimesine (CT1812). The Phase 3 program is expected to start mid-2027; it will randomize patients to 100 mg once-daily zervimesine vs placebo for nine months, using NPI as a primary endpoint.
4 min readCOGNITION THERAPEUTICS INC (CGTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001455365 0001455365 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report
2 min readCognition Therapeutics (Nasdaq: CGTX) said CEO Lisa Ricciardi will present at two investor conferences in June, sharing updates on the company’s planned registrational program for dementia with Lewy body (DLB) psychosis. The Jefferies Global Healthcare Conference is June 4, 2026 (1:25 p.m. ET), with an on-demand H.C. Wainwright summit starting June 15. Webcasts will be available on the company’s site.
2 min readFive brokerages have given Cognition Therapeutics (NASDAQ:CGTX) a "Moderate Buy" consensus rating, with an average 1-year price target of $3.33. Institutional ownership has increased significantly to 43.35%, driven by major stake builds and new positions. Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on Alzheimer's, with its lead candidate CT1812 currently in multiple Phase 2 trials.
2 min readStudy conducted in collaboration with the Alzheimer's Clinical Trials Consortium Study conducted in collaboration with the Alzheimer's Clinical Trials Consortium ...
2 min readHere is how ANI Pharmaceuticals (ANIP) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.
3 min readCognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 min read- The offering was made to two new fundamental institutional investors ...
2 min read
